We have located links that may give you full text access.
The burden of cutaneous adnexal carcinomas and the risk of associated squamous cell carcinoma: a population-based study.
British Journal of Dermatology 2018 October 17
BACKGROUND: Recent studies have shown an increasing incidence of cutaneous adnexal carcinomas (CACs) over the years.
OBJECTIVE: The aim of our study was to evaluate incidence and survival of CACsand investigate their association with other skin neoplasms.
METHODS: Population based study. Data on incident cases of CACs were obtained from the Tuscany Cancer Registry (TCR) between 1985 and 2010. In order to determine if the occurence of squamous cell carcinoma (SCC) among patients with CAC is higher or lower than expected in the general population, standardized incidence ratio (SIR) was calculated.
RESULTS: 242 patients with CAC were observed; age-standardized incidence rate was 3·8 cases per millionperson-years. From 1997 to 2010, crude-incidence rates increased by 159%. Age-specific incidence was higher in males over 80 year-oldthan females of the same age and younger individuals. Carcinomas of sweat gland originprevailed; the most common histotype was porocarcinoma and the most frequentlyaffected site was the head-neck. 88% of CACs was diagnosed at a localized stage. 5-year overall survival and disease-specific survival rates were 59% (95%CI 53-65) and 94% (95%CI 91-98), respectively. In observation cohort, number of SCC was significantly higher than expected as SIR resulted 33·7 (p<0·0001).
CONCLUSION: Increasing incidence warrants awareness and early diagnosis of cutaneous adnexal carcinomas. Increased SCC incidence among patients with these tumors highlights relevance of careful skin examination and follow-up. This article is protected by copyright. All rights reserved.
OBJECTIVE: The aim of our study was to evaluate incidence and survival of CACsand investigate their association with other skin neoplasms.
METHODS: Population based study. Data on incident cases of CACs were obtained from the Tuscany Cancer Registry (TCR) between 1985 and 2010. In order to determine if the occurence of squamous cell carcinoma (SCC) among patients with CAC is higher or lower than expected in the general population, standardized incidence ratio (SIR) was calculated.
RESULTS: 242 patients with CAC were observed; age-standardized incidence rate was 3·8 cases per millionperson-years. From 1997 to 2010, crude-incidence rates increased by 159%. Age-specific incidence was higher in males over 80 year-oldthan females of the same age and younger individuals. Carcinomas of sweat gland originprevailed; the most common histotype was porocarcinoma and the most frequentlyaffected site was the head-neck. 88% of CACs was diagnosed at a localized stage. 5-year overall survival and disease-specific survival rates were 59% (95%CI 53-65) and 94% (95%CI 91-98), respectively. In observation cohort, number of SCC was significantly higher than expected as SIR resulted 33·7 (p<0·0001).
CONCLUSION: Increasing incidence warrants awareness and early diagnosis of cutaneous adnexal carcinomas. Increased SCC incidence among patients with these tumors highlights relevance of careful skin examination and follow-up. This article is protected by copyright. All rights reserved.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app